266 related articles for article (PubMed ID: 25031539)
1. Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review.
Marchetti C; Palaia I; Giorgini M; De Medici C; Iadarola R; Vertechy L; Domenici L; Di Donato V; Tomao F; Muzii L; Benedetti Panici P
Onco Targets Ther; 2014; 7():1223-36. PubMed ID: 25031539
[TBL] [Abstract][Full Text] [Related]
2. Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments.
Ledermann JA; Canevari S; Thigpen T
Ann Oncol; 2015 Oct; 26(10):2034-43. PubMed ID: 26063635
[TBL] [Abstract][Full Text] [Related]
3. The folate receptor as a rational therapeutic target for personalized cancer treatment.
Assaraf YG; Leamon CP; Reddy JA
Drug Resist Updat; 2014; 17(4-6):89-95. PubMed ID: 25457975
[TBL] [Abstract][Full Text] [Related]
4. Targeted treatment of folate receptor-positive platinum-resistant ovarian cancer and companion diagnostics, with specific focus on vintafolide and etarfolatide.
Serpe L; Gallicchio M; Canaparo R; Dosio F
Pharmgenomics Pers Med; 2014; 7():31-42. PubMed ID: 24516337
[TBL] [Abstract][Full Text] [Related]
5. Folate and folate receptor alpha antagonists mechanism of action in ovarian cancer.
Walters CL; Arend RC; Armstrong DK; Naumann RW; Alvarez RD
Gynecol Oncol; 2013 Nov; 131(2):493-8. PubMed ID: 23863359
[TBL] [Abstract][Full Text] [Related]
6. Clinical translation of folate receptor-targeted therapeutics.
Teng L; Xie J; Teng L; Lee RJ
Expert Opin Drug Deliv; 2012 Aug; 9(8):901-8. PubMed ID: 22663189
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of treatment of advanced ovarian cancer with folate-receptor-targeted therapeutic (vintafolide) and companion SPECT-based imaging agent (99mTc-etarfolatide).
Morris RT; Joyrich RN; Naumann RW; Shah NP; Maurer AH; Strauss HW; Uszler JM; Symanowski JT; Ellis PR; Harb WA
Ann Oncol; 2014 Apr; 25(4):852-858. PubMed ID: 24667717
[TBL] [Abstract][Full Text] [Related]
8. Profile of vintafolide (EC145) and its use in the treatment of platinum-resistant ovarian cancer.
Luyckx M; Votino R; Squifflet JL; Baurain JF
Int J Womens Health; 2014; 6():351-8. PubMed ID: 24729732
[TBL] [Abstract][Full Text] [Related]
9. Clinical trials and future potential of targeted therapy for ovarian cancer.
Itamochi H; Kigawa J
Int J Clin Oncol; 2012 Oct; 17(5):430-40. PubMed ID: 22926640
[TBL] [Abstract][Full Text] [Related]
10. PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer.
Naumann RW; Coleman RL; Burger RA; Sausville EA; Kutarska E; Ghamande SA; Gabrail NY; Depasquale SE; Nowara E; Gilbert L; Gersh RH; Teneriello MG; Harb WA; Konstantinopoulos PA; Penson RT; Symanowski JT; Lovejoy CD; Leamon CP; Morgenstern DE; Messmann RA
J Clin Oncol; 2013 Dec; 31(35):4400-6. PubMed ID: 24127448
[TBL] [Abstract][Full Text] [Related]
11. Vintafolide: a novel targeted therapy for the treatment of folate receptor expressing tumors.
Vergote I; Leamon CP
Ther Adv Med Oncol; 2015 Jul; 7(4):206-18. PubMed ID: 26136852
[TBL] [Abstract][Full Text] [Related]
12. Imaging the folate receptor on cancer cells with 99mTc-etarfolatide: properties, clinical use, and future potential of folate receptor imaging.
Maurer AH; Elsinga P; Fanti S; Nguyen B; Oyen WJ; Weber WA
J Nucl Med; 2014 May; 55(5):701-4. PubMed ID: 24732155
[TBL] [Abstract][Full Text] [Related]
13. Clinical Trials of Novel Targeted Therapies in Ovarian Cancer: Moving Beyond Poly ADP Ribose Polymerase (PARP) Inhibitors.
Guo Q; Yang Q; Li J; Liu G; Nikoulin I; Jia S
Curr Pharm Biotechnol; 2018; 19(14):1114-1121. PubMed ID: 30585545
[TBL] [Abstract][Full Text] [Related]
14. Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications.
Vergote IB; Marth C; Coleman RL
Cancer Metastasis Rev; 2015 Mar; 34(1):41-52. PubMed ID: 25564455
[TBL] [Abstract][Full Text] [Related]
15. High Levels of Expression of P-glycoprotein/Multidrug Resistance Protein Result in Resistance to Vintafolide.
Guertin AD; O'Neil J; Stoeck A; Reddy JA; Cristescu R; Haines BB; Hinton MC; Dorton R; Bloomfield A; Nelson M; Vetzel M; Lejnine S; Nebozhyn M; Zhang T; Loboda A; Picard KL; Schmidt EV; Dussault I; Leamon CP
Mol Cancer Ther; 2016 Aug; 15(8):1998-2008. PubMed ID: 27256377
[TBL] [Abstract][Full Text] [Related]
16. Vintafolide (EC145) for the treatment of folate-receptor-α positive platinum-resistant ovarian cancer.
Ambrosio AJ; Suzin D; Palmer EL; Penson RT
Expert Rev Clin Pharmacol; 2014 Jul; 7(4):443-50. PubMed ID: 24742319
[TBL] [Abstract][Full Text] [Related]
17. Folate receptor alpha antagonists in preclinical and early stage clinical development for the treatment of epithelial ovarian cancer.
Bergamini A; Ferrero S; Leone Roberti Maggiore U; Scala C; Pella F; Vellone VG; Petrone M; Rabaiotti E; Cioffi R; Candiani M; Mangili G
Expert Opin Investig Drugs; 2016 Dec; 25(12):1405-1412. PubMed ID: 27797594
[TBL] [Abstract][Full Text] [Related]
18. Targeted drug delivery via folate receptors.
Zhao X; Li H; Lee RJ
Expert Opin Drug Deliv; 2008 Mar; 5(3):309-19. PubMed ID: 18318652
[TBL] [Abstract][Full Text] [Related]
19. Profile of farletuzumab and its potential in the treatment of solid tumors.
Sato S; Itamochi H
Onco Targets Ther; 2016; 9():1181-8. PubMed ID: 27022278
[TBL] [Abstract][Full Text] [Related]
20. Targeted agents in epithelial ovarian cancer: review on emerging therapies and future developments.
Lokadasan R; James FV; Narayanan G; Prabhakaran PK
Ecancermedicalscience; 2016; 10():626. PubMed ID: 27110282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
